SCM
PVLA

Sterling Capital Management’s Palvella Therapeutics PVLA Stock Holding History

Sterling Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.96K Sell
39
-27
-41% -$3.28K ﹤0.01% 2518
2026
Q1 		$8.23K Sell
66
-7
-10% -$730 ﹤0.01% 2485
2025
Q4 		$7.64K Buy
73
+26
+55% +$2.22K ﹤0.01% 2734
2025
Q3 		$2.95K Buy
47
+20
+74% +$892 ﹤0.01% 2914
2025
Q2 		$609 Buy
+27
New +$634 ﹤0.01% 3131

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Sterling Capital Management's PVLA Position: Q2 2026 in Review

Sterling Capital Management reduced its Palvella Therapeutics (PVLA) stake by 41% in Q2 2026, selling an estimated $3.28K and leaving 39 shares worth $5.96K. The position accounts for ﹤0.01% of the portfolio, ranked #2518.

Sterling Capital Management first reported a position in PVLA in Q2 2025 and has held it in 5 quarters since. The position peaked at $8.23K in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Sterling Capital Management held 39 shares of Palvella Therapeutics worth $5.96K as of Q2 2026.
  • Sterling Capital Management sold 27 Palvella Therapeutics shares in Q2 2026, an estimated $3.28K.
  • Palvella Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2518 holding.
  • Sterling Capital Management first reported a position in Palvella Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Sterling Capital Management's Palvella Therapeutics position peaked at $8.23K in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.